tiprankstipranks
Trending News
More News >
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
US Market
Advertisement

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Compare
1,487 Followers
See the Price Targets and Ratings of:

NKTR Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
6 Buy
1 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Nektar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$96.17
▲(228.45% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $96.17 with a high forecast of $120.00 and a low forecast of $69.00. The average price target represents a 228.45% change from the last price of $29.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","121":"$121","36.25":"$36.3","64.5":"$64.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$96.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,36.25,64.5,92.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,30.424615384615386,37.88923076923077,45.35384615384615,52.818461538461534,60.28307692307692,67.7476923076923,75.21230769230769,82.67692307692307,90.14153846153846,97.60615384615383,105.07076923076923,112.5353846153846,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,28.591538461538462,34.223076923076924,39.854615384615386,45.486153846153854,51.11769230769231,56.74923076923078,62.38076923076924,68.0123076923077,73.64384615384617,79.27538461538462,84.90692307692308,90.53846153846155,{"y":96.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,26.501538461538463,30.043076923076924,33.58461538461538,37.12615384615385,40.667692307692306,44.20923076923077,47.75076923076923,51.29230769230769,54.83384615384615,58.37538461538461,61.91692307692308,65.45846153846153,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.75,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.05,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$96.17Lowest Price Target$69.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on NKTR
TR | OpenAI - 4o
TR | OpenAI - 4o
$23.5$26
Hold
-11.20%
Downside
Reiterated
08/14/25
AI Generated ArticleAI Generated Article
BTIG
$100
Buy
241.53%
Upside
Reiterated
08/08/25
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR)We hosted a webcast discussion last week with Dr. Charles Gropper (St. Sinai) who viewed REZPEG's therapeutic profile as a novel MOA favorably. Also of note, we hosted a dermatology payor call earlier this year, where it was unequivocally clear that new atopic dermatitis therapies that have at least parity efficacy vs. Dupixent should be warmly welcomed by the market. Looking ahead, we are focused on Phase 2b data of REZPEG in alopecia areata (REZOLVE-AA) expected in December 2025. JAK inhibitors are currently the only approved Tx for alopecia and come with significant safety concerns. Mgmt. considers efficacy similar to the JAK inhibitors (30-40% SALT reduction) as meaningful and while not required for success, even sees a compelling possibility for greater efficacy based on REZPEG's mechanism.
H.C. Wainwright Analyst forecast on NKTR
H.C. Wainwright
H.C. Wainwright
$120
Buy
309.84%
Upside
Reiterated
08/08/25
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance
Piper Sandler Analyst forecast on NKTR
Piper Sandler
Piper Sandler
$105
Buy
258.61%
Upside
Reiterated
08/08/25
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Oppenheimer Analyst forecast on NKTR
Oppenheimer
Oppenheimer
$90$98
Buy
234.70%
Upside
Reiterated
08/08/25
Nektar price target raised to $98 from $90 at OppenheimerNektar price target raised to $98 from $90 at Oppenheimer
William Blair Analyst forecast on NKTR
William Blair
William Blair
Hold
Reiterated
08/08/25
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments
B.Riley Financial Analyst forecast on NKTR
B.Riley Financial
B.Riley Financial
$60$85
Buy
190.30%
Upside
Reiterated
07/08/25
Nektar price target raised to $85 from $60 at B. RileyNektar price target raised to $85 from $60 at B. Riley
J.P. Morgan Analyst forecast on NKTR
J.P. Morgan
J.P. Morgan
Sell
Reiterated
06/24/25
J.P. Morgan Sticks to Its Sell Rating for Nektar Therapeutics (NKTR)
Jefferies Analyst forecast on NKTR
Jefferies
Jefferies
$69
Buy
135.66%
Upside
Reiterated
06/24/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on NKTR
TR | OpenAI - 4o
TR | OpenAI - 4o
$23.5$26
Hold
-11.20%
Downside
Reiterated
08/14/25
AI Generated ArticleAI Generated Article
BTIG
$100
Buy
241.53%
Upside
Reiterated
08/08/25
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR)We hosted a webcast discussion last week with Dr. Charles Gropper (St. Sinai) who viewed REZPEG's therapeutic profile as a novel MOA favorably. Also of note, we hosted a dermatology payor call earlier this year, where it was unequivocally clear that new atopic dermatitis therapies that have at least parity efficacy vs. Dupixent should be warmly welcomed by the market. Looking ahead, we are focused on Phase 2b data of REZPEG in alopecia areata (REZOLVE-AA) expected in December 2025. JAK inhibitors are currently the only approved Tx for alopecia and come with significant safety concerns. Mgmt. considers efficacy similar to the JAK inhibitors (30-40% SALT reduction) as meaningful and while not required for success, even sees a compelling possibility for greater efficacy based on REZPEG's mechanism.
H.C. Wainwright Analyst forecast on NKTR
H.C. Wainwright
H.C. Wainwright
$120
Buy
309.84%
Upside
Reiterated
08/08/25
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance
Piper Sandler Analyst forecast on NKTR
Piper Sandler
Piper Sandler
$105
Buy
258.61%
Upside
Reiterated
08/08/25
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Oppenheimer Analyst forecast on NKTR
Oppenheimer
Oppenheimer
$90$98
Buy
234.70%
Upside
Reiterated
08/08/25
Nektar price target raised to $98 from $90 at OppenheimerNektar price target raised to $98 from $90 at Oppenheimer
William Blair Analyst forecast on NKTR
William Blair
William Blair
Hold
Reiterated
08/08/25
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments
B.Riley Financial Analyst forecast on NKTR
B.Riley Financial
B.Riley Financial
$60$85
Buy
190.30%
Upside
Reiterated
07/08/25
Nektar price target raised to $85 from $60 at B. RileyNektar price target raised to $85 from $60 at B. Riley
J.P. Morgan Analyst forecast on NKTR
J.P. Morgan
J.P. Morgan
Sell
Reiterated
06/24/25
J.P. Morgan Sticks to Its Sell Rating for Nektar Therapeutics (NKTR)
Jefferies Analyst forecast on NKTR
Jefferies
Jefferies
$69
Buy
135.66%
Upside
Reiterated
06/24/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

1 Month
xxx
Success Rate
9/18 ratings generated profit
50%
Average Return
+1.47%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.47% per trade.
3 Months
xxx
Success Rate
4/8 ratings generated profit
50%
Average Return
+8.30%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +8.30% per trade.
1 Year
Success Rate
8/8 ratings generated profit
100%
Average Return
+72.99%
reiterated a buy rating 21 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.99% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
100%
Average Return
+72.99%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +72.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
11
10
9
11
11
Buy
0
0
0
0
0
Hold
5
10
16
19
16
Sell
1
0
3
3
3
Strong Sell
0
0
0
0
0
total
17
20
28
33
30
In the current month, NKTR has received 11 Buy Ratings, 16 Hold Ratings, and 3 Sell Ratings. NKTR average Analyst price target in the past 3 months is 96.17.
Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$2.79 with a range of -$3.23 to -$2.33. The previous quarter’s EPS was -$2.95. NKTR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.
Next quarter’s earnings estimate for NKTR is -$2.79 with a range of -$3.23 to -$2.33. The previous quarter’s EPS was -$2.95. NKTR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $10.16M with a range of $6.00M to $13.06M. The previous quarter’s sales results were $11.18M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.
Next quarter’s sales forecast for NKTR is $10.16M with a range of $6.00M to $13.06M. The previous quarter’s sales results were $11.18M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 96.17.
    What is NKTR’s upside potential, based on the analysts’ average price target?
    Nektar Therapeutics has 228.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NKTR a Buy, Sell or Hold?
          Nektar Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Nektar Therapeutics’s price target?
            The average price target for Nektar Therapeutics is 96.17. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $69.00. The average price target represents 228.45% Increase from the current price of $29.28.
              What do analysts say about Nektar Therapeutics?
              Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of NKTR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis